Medical Oncology

, Volume 28, Supplement 1, pp 570–576

Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases

  • Liang-Ping Xia
  • Hui-Juan Qiu
  • Xu-Xian Chen
  • Pi-Li Hu
  • Gui-Fang Guo
  • Fang Wang
  • Fei-Fei Zhou
  • Wen-Zhuo He
  • Bei Zhang
  • Li Zhang
Original Paper

Abstract

Cetuximab combined with chemotherapy has been used to treat Non-small cell lung cancer (NSCLC) in recent years, however, the data from China was rare. This study was to summarize our experiences in treating NSCLC patients with cetuximab in the first line setting. From October 1st 2006 to Jun 30th 2010, twelve NSCLC patients were treated with cetuximab combined standard chemotherapy as first line setting in Sun Yat-sen University Cancer Center entered the study and the short-term efficacy and safety were analyzed. A total of 132 cycles of cetuximab treatment, with a median of nine cycles in the whole group were administered. The ORR was 41.7% (5/12), DCR was 83.3% (10/12), median TTP was 5.5 months (2–23), and median OS was 9 months (2–48) in the whole group. There were 75% (9/12) patients occurred acne-like rash within first 3 weeks, their ORR was 55.6% (5/9), DCR was 100% (9/9), however, ORR and DCR in patients who didn’t occurred acne-like rash within first 3 weeks were 0 and 33.3% (1/3), the difference ORR between two group was insignificant (P = 0.091), however, DCR was significant different (P = 0.007). There no treatment-associated death and no cetuximab-associated discontinuation. The incidence of acne-like rash was 83.3% (10/12) and 75% (9/12) occurred within first 3 weeks, there were eight patients suffered side effects associated with chemotherapy. So we can draw a conclusion that the short-term outcome of cetuximab application in first line setting for patients with NSCLC were promising since the higher ORR and DCR, especially those occurred acne-like rash within the first 3 weeks, and the addition of cetuximab in this population was safe.

Keywords

Cetuximab Non-small cell lung cancer Efficacy Safety First line Chemotherapy 

Abbreviations

NSCLC

Non-small cell lung cancer

CR

Complete response

PR

Partial response

SD

Stable disease

PD

Progression disease

ORR

Overall response rate

DCR

Disease control rate

TTP

Time to progression

OS

Overall survival

EGFR

Epidermal growth factor receptor

TKIs

Tyrosine kinase inhibitors

FLEX

First-line treatment for patients with EGFR-EXpressing advanced NSCLC

ASCO

American Society of Clinical Oncology

NCCN

National Comprehensive Cancer Network

WCLC

World Conference on Lung Cancer

References

  1. 1.
    Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.PubMedCrossRefGoogle Scholar
  2. 2.
    Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.PubMedCrossRefGoogle Scholar
  3. 3.
    Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.PubMedCrossRefGoogle Scholar
  5. 5.
    Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006;1(8):847–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Cappuzzo, Ciuleanu T, Stelmah L, et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with 1st-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol. 2009;27(18S):15s(abstr 8001).Google Scholar
  7. 7.
    Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of West Japan Thoracic Oncology Group trial (WJTOG). J Clin Oncol. 2008;26(15S):427s(LBA8012).Google Scholar
  8. 8.
    Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Socinski MA, Saleh MN, Trent DF, et al. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol. 2009;20(6):1068–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Borghaei H, Langer CJ, Millenson M, et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008;3(11):1286–92.PubMedCrossRefGoogle Scholar
  11. 11.
    Belani CP, Schreeder MT, Steis RG, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008;113(9):2512–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol. 2007;25(36):5777–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol. 2008;19(2):362–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(36):9089–96.PubMedCrossRefGoogle Scholar
  15. 15.
    Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005;23(34):8786–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line Taxane/Carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010;28(6):911–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Thatcher N, Linchy TJ, Butts CA, et al. Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer(NSCLC)[C]:A meta-analysis of randomized phase II/III trails. WCLC 2009, oral presentation (abstract A3.7).Google Scholar
  18. 18.
    Lin H, Jiang J, Liang X, et al. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2010;70(1):57–62.CrossRefGoogle Scholar
  19. 19.
    Xia LP, Rong YM, Guo GF, et al. The summary of efficacy of cetuximab combination with chemotherapy in NSCLC first-line setting: based on publication. Chin-Ger J Clin Oncol. 2010;9(3):137–41.CrossRefGoogle Scholar
  20. 20.
    Langer CJ. Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting. Clin Lung Cancer. 2008;9(5):249–51.PubMedCrossRefGoogle Scholar
  21. 21.
    Xia LP, Zhang Li, Zhang B, et al. Short-term efficacy of patients with non-small cell lung cancer treated by cetuximab plus chemotherapy: review and 2 cases report. J Oncol. 2010;16(2):133–8.Google Scholar
  22. 22.
    Wang F, Xia LP, Guo GF, et al. Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with Non-small cell lung cancer: a report of 6 cases. Chin-Ger J Clin Oncol. 2010;9(9):502–6.CrossRefGoogle Scholar
  23. 23.
    Xia LP, Zang B, Liu MZ, et al. Short-term efficacy of cetuximab combined with radiotherapy or chemotherapy on head and neck cancer: a report of 11 cases. Chin J Cancer (Chin). 2009;29(9):977–82.Google Scholar
  24. 24.
    Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993;53(19):4637–42.PubMedGoogle Scholar
  25. 25.
    Fan Z, Lu Y, Wu X, et al. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994;269(44):27595–602.PubMedGoogle Scholar
  26. 26.
    Xia LP, Guo GF, Qiu HJ, et al. Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer. Chin-Ger J Clin Oncol. 2009;8(9):526–30.CrossRefGoogle Scholar
  27. 27.
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.PubMedCrossRefGoogle Scholar
  28. 28.
    Hirsch FR, Herbst RS, Olsen C. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008;26(20):3351–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(6):918–27.PubMedCrossRefGoogle Scholar
  30. 30.
    Gatzemeier U. FLEX: Cetuximab in combination with platinum-based chemotherapy (CT) improves survival versus chemotherapy (CT) alone in the 1st-line treatment of patients with advanced non-small cell lung caner(NSCLC)[C]. Data presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. J Thorac Oncol. 2008;3:S4. Abstract 8.Google Scholar
  31. 31.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Jatoi A, Green EM, Rowland KM Jr, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology. 2009;77(2):120–3.PubMedCrossRefGoogle Scholar
  33. 33.
    Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Liang-Ping Xia
    • 1
    • 2
  • Hui-Juan Qiu
    • 1
    • 2
  • Xu-Xian Chen
    • 1
    • 2
  • Pi-Li Hu
    • 1
    • 2
  • Gui-Fang Guo
    • 1
    • 2
  • Fang Wang
    • 1
    • 2
  • Fei-Fei Zhou
    • 3
  • Wen-Zhuo He
    • 1
    • 2
  • Bei Zhang
    • 1
    • 2
  • Li Zhang
    • 1
    • 4
  1. 1.State Key Laboratory of Oncology in South ChinaGuangzhouPeople’s Republic of China
  2. 2.VIP Region, Sun Yat-sen University Cancer CenterGuangzhouPeople’s Republic of China
  3. 3.Tumor Center, The Foshan First People’s HospitalFoshanPeople’s Republic of China
  4. 4.Department of Medical OncologySun Yat-sen University Cancer CenterGuangzhouPeople’s Republic of China

Personalised recommendations